BioStem completes BR-AC venous ulcer trial; Kardigan finishes KATALYST-AV aortic stenosis enrollment
Two unrelated updates this week: a completed BioStem wound-care trial and completed enrollment in Kardigan's Phase 2b aortic stenosis study.
This week brought one trial completion and one enrollment milestone.
- The study tested whether weekly applications of BR-AC alongside standard care would produce a higher proportion of complete wound healing within 12 weeks compared to standard care alone.1
- Kardigan announced it has completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis.
Fact check notes
- Sentence removed
BioStem Technologies' randomized, controlled trial of BR-AC, a human placental allograft, for non-healing venous leg ulcers is listed as completed, with 71 participants enrolled.
a figure with no citation - Sentence removed
The company said the primary endpoint of aortic valve calcium will be assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function, with topline data expected in the second half of 2027.
copied source wording
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.